Brian Kenney 💥 (@BKenney1) header
Brian Kenney 💥 (@BKenney1) profile picture

Brian Kenney 💥

@BKenney1

Championing 📢 science 🧬 #Communications. 💯% #Philly fan #Jeep o|||||||o @LaSalleUniv alum. Jawns all mine.

 The Great Philadelphia Area
linkedin.com/in/briankenney1/
Joined November 2008
  • Tweets9.3K
  • Following4.7K
  • Followers2.4K
1.3KMedia
Photo by Brian Kenney 💥 (@BKenney1)Photo by Brian Kenney 💥 (@BKenney1)Photo by Brian Kenney 💥 (@BKenney1)Photo by Brian Kenney 💥 (@BKenney1)Photo by Brian Kenney 💥 (@BKenney1)Photo by Brian Kenney 💥 (@BKenney1)Photo by Brian Kenney 💥 (@BKenney1)Photo by Brian Kenney 💥 (@BKenney1)Photo by Brian Kenney 💥 (@BKenney1)
The Waiting is the Hardest Part linkedin.com/pulse/waiting-h…
The Waiting is the Hardest Part

The Waiting is the Hardest Part

For some, this phrase may evoke one’s best Tom Petty and the Heartbreakers impression of “The Wait” -- go ahead, belt it out, you know you want to. It seems our whole life we wait.

linkedin.com
3
5
2
20
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled cnb.cx/3WauDZx @Genmab
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.

cnbc.com
52
Moderna shares plunge after leak of cancer vaccine data despite positive results cnb.cx/4ikVklI
Moderna shares plunge after cancer vaccine data leaks — despite positive results

Moderna shares plunge after cancer vaccine data leaks — despite positive results

Moderna released full data on its closely watched cancer vaccine developed with Merck.

cnbc.com
88
Great interview by @BiotechTV's @bradloncar with superb perspective from @BarclaysCIB analyst Ellie Merle - no doubt @Merck & @moderna_tx data going to huge @ESMO2026
BiotechTV (@BiotechTV) profile pictureBiotechTV
@BiotechTVOct 21
𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @BarclaysCIB Biotech Analyst Ellie Merle previews this weekend's highly anticipated cancer vaccine data from Merck and Moderna at ESMO. She sees scenarios for the stock ranging from $100 to mid $400's. $MRK $MRNA Full video: biotechtv.com/post/ellie-mer…
145
Everybody ... 👏 ...
Philadelphia 76ers (@sixers) profile picturePhiladelphia 76ers
@sixersOct 20
the time has come. @Bloom_Energy
28
wow
Gino Hard (@GinoHard_) profile pictureGino Hard
@GinoHard_Oct 18
TRENT FREDERIC AND JACK MCBAIN DROP THE GLOVES AND EXCHANGE SOME ABSOLUTE BOMBS WOW 😵🥊
43
Molecular glue degraders show early promise in reducing Alzheimer's-linked brain plaques medicalxpress.com/news/2026-… via @medical_xpress
Molecular glue degraders show early promise in reducing Alzheimer's-linked brain plaques

Molecular glue degraders show early promise in reducing Alzheimer's-linked brain plaques

A research team led by Indiana University School of Medicine scientists has discovered a new method for reducing the formation of amyloid plaques, which disrupt brain function in all aging adults but...

medicalxpress.com
36
MimiVax's cancer vaccine for glioblastoma narrowly misses Phase 2b goal - endpoints.news/mimivaxs-canc…
Vaccine for deadly brain cancer narrowly misses goal in key trial

Vaccine for deadly brain cancer narrowly misses goal in key trial

MimiVax's glioblastoma vaccine SurVaxM narrowly misses Ph2b OS goal but shows 4-month gain in patients 65 and under.

endpoints.news
35
What time are the @NHLFlyers supposed to arrive tonight?
49
Biotech's best startups of 2026: Meet this year's Endpoints 11 - endpoints.news/biotechs-best…
Biotech's most exciting startups of 2026: Meet this year's Endpoints 11

Biotech's most exciting startups of 2026: Meet this year's Endpoints 11

Endpoints News announces the winners of the 2026 Endpoints 11 awards: The best and most exiting biotech startups of the year.

endpoints.news
1
63
As @Phillies fade @NHLFlyers rise
Image from Brian Kenney 💥 (@BKenney1)
71
🙌 Wegovy maker Novo Nordisk is rebranding as Novo, betting a shorter name will help it resonate more with consumers as it competes with rival Eli Lilly. wsj.com/health/pharma/novo-n… via @WSJ
Novo Nordisk Slims Down Name to Novo

Novo Nordisk Slims Down Name to Novo

The drugmaker said its new name aims to make it more recognizable to compete in the market for obesity medications.

wsj.com
1
1
234
Penn startup @DispatchBio launches first human trial for solid tumor cancer treatment thedp.com/article/2026/09/pe… @dailypenn
Penn startup launches first human trial for solid tumor cancer treatment

Penn startup launches first human trial for solid tumor cancer treatment

Johnson said he hopes the cell therapy will eventually produce “robust” and “long-lived” effects that extend patients’ life expectancies. 

thedp.com
1
63
Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T - endpoints.news/bristol-myers…
Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T

Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T

An experimental CAR-T called arlo-cel improved response rates in patients with relapsed and refractory multiple myeloma who had received at least four previous therapies.

endpoints.news
50
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns biopharmadive.com/news/novar… via @BioPharmaDive
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns

Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns

The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient” side effects pushed Bristol Myers to voluntarily pause its zola-cel...

biopharmadive.com
1
278
FDA approves Revolution Medicines' pancreatic cancer drug - endpoints.news/fda-approves-…
FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

FDA approves Revolution Medicines' daraxonrasib (Rasonque) for second-line pancreatic cancer, after it nearly doubled survival in a Phase 3 to 13.2 months vs. 6.7 months on chemo.

endpoints.news
57
Fred Hutch researchers discover molecular switch that helps prostate cancer quickly change its biology to evade therapy fredhutch.org/content/www/en… via @fredhutch
Fred Hutch researchers discover molecular switch that helps prostate cancer quickly change its...

Fred Hutch researchers discover molecular switch that helps prostate cancer quickly change its...

Fred Hutch researchers show in recent study how aggressive prostate cancer shapeshifts from a form that is treatable with drugs to a more lethal form that is much less treatable. The study also...

fredhutch.org
1
46
FDA approves breakthrough drug to treat advanced pancreatic cancer abcnews.com/Health/fda-appro…

FDA approves breakthrough drug to treat advanced pancreatic cancer

The Food and Drug Administration approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer.

abcnews.com
1
83
So sad and on so many levels | Hayden Panettiere's death sparks renewed backlash against Neutrogena usatoday.com/story/entertain… via @usatoday
Neutrogena speaks out after Hayden Panettiere's death sparks renewed backlash

Neutrogena speaks out after Hayden Panettiere's death sparks renewed backlash

Hayden Panettiere alleged Neutrogena tried to fire her for speaking about postpartum depression. After her death, the backlash reached a new pitch.

usatoday.com
48
Moderna $30 bln gain implies many cancer successes reuters.com/commentary/break…
Breakingviews - COMMENTARY: Moderna $30 bln gain implies many cancer successes

Breakingviews - COMMENTARY: Moderna $30 bln gain implies many cancer successes

The biotech’s equity value rose over 100% ‌on news that a trial of a new vaccine prevented recurrence in melanoma. A profit share with Merck means ​the market is implying sales may reach a ​stunning...

reuters.com
51
New way to help CAR-T cells fight solid tumors could change cancer treatment medicalxpress.com/news/2026-… via @medical_xpress
New way to help CAR-T cells fight solid tumors could change cancer treatment

New way to help CAR-T cells fight solid tumors could change cancer treatment

For more than a decade, CAR-T cell therapy has been one of the biggest breakthroughs in cancer medicine. By reprogramming a patient's own immune cells to attack cancer, doctors have produced remark...

medicalxpress.com
25
Load more